Cargando…
Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection
The current outbreak of severe acute respiratory distress syndrome (SARS) or nCOVID-19 pandemic, caused by the coronavirus-2 (CoV-2), continues to wreak havoc globally. As novel vaccines are being discovered and developed, small molecule drugs still constitute a viable treatment option for SARS-CoV-...
Autores principales: | Rao, Praveen P. N., Pham, Amy Trinh, Shakeri, Arash, El Shatshat, Amna, Zhao, Yusheng, Karuturi, Rahul C., Hefny, Ahmed A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827924/ https://www.ncbi.nlm.nih.gov/pubmed/33430081 http://dx.doi.org/10.3390/ph14010044 |
Ejemplares similares
-
Downregulation of Signaling-active IGF-1 by Dipeptidyl Peptidase IV (DPP-IV)
por: Lin, Ching-Ting, et al.
Publicado: (2010) -
Rapid Identification of Dipeptidyl Peptidase-IV (DPP-IV) Inhibitory Peptides from Ruditapes philippinarum Hydrolysate
por: Liu, Rui, et al.
Publicado: (2017) -
Elevated Dipeptidyl Peptidase IV (DPP-IV) Activity in Plasma from Patients with Various Lysosomal Diseases
por: Ługowska, Agnieszka, et al.
Publicado: (2021) -
Dipeptidyl peptidase-4 (DPP-4; CD26)
Publicado: (2013) -
Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19
por: Solerte, Sebastiano Bruno, et al.
Publicado: (2020)